Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational HighlightsRead More
Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)Read More
Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences ConferenceRead More
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational HighlightsRead More